AbbVie says FDA approves Skyrizi for ulcerative colitis
AbbVie said that the heavily-advertised drug was now approved for four conditions across different so-called “immune-mediated” inflammatory diseases.
AbbVie said that the heavily-advertised drug was now approved for four conditions across different so-called “immune-mediated” inflammatory diseases.
